Biohaven reports positive phase 1 degrader data, achieving deep targeted igg reductions in the lowest subcutaneous dose tested; announces nda submission for troriluzole in sca and provides other key program updates

Bhv-1300 achieved deep lowering of targeted igg, with reductions > 60% in the lowest subcutaneous dose tested in the mad. subcutaneous bhv-1300 achieved rapid and progressive lowering of igg within hours of each weekly dose administration, and pharmacodynamic effects were sustained relative to baseline over the four-week period.
BHVN Ratings Summary
BHVN Quant Ranking